Leap Therapeutics

$2.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (+2.48%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell LPTX and other stocks, options, and ETFs commission-free!

About LPTX

Leap Therapeutics, Inc. Common Stock, also called Leap Therapeutics, is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01, which is a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1 and TRX518, which is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA. The listed name for LPTX is Leap Therapeutics, Inc. Common Stock.

CEO

Doug E. Onsi

Employees

Headquarters

Cambridge, Massachusetts

Founded

2011

Market Cap

146.73M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

734.09K

High Today

$2.67

Low Today

$2.36

Open Price

$2.39

Volume

1.03M

52 Week High

$3.18

52 Week Low

$1.15

Collections

LPTX Earnings

-$0.55

-$0.37

-$0.18

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 15, Pre-Market